DB00238ApprovedInvestigationalSmall moleculeHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorNonnucleoside Reverse Transcriptase Inhibitors
Nevirapine is a non-nucleoside reverse transcriptase inhibitor used as part of a management regimen for HIV-1 virus infection. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Mechanism
- Curator reviewed
Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
- Primary indication
- For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.Curator reviewed · 1 structured indication
- Formula / weight
- C15H14N4O · 266.2979 g/mol (avg)
- First approval
- Canada, 1998 · United States, 2001 · European Union, 2016
- Code names
- BIRG-0587 · BIRG-587 · NSC-641530
- Brand names
Resolves to
Structure
InChIKey
NQDJXKOVJZTUJA-UHFFFAOYSA-NSMILESCC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1Targets
Transporters
What you can answer from here — as of September 13, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Nevirapine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account